Podium Poster Presentations

Introduction & Objectives: Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) continue to present a significant disease burden. The morbidity associated with traditional transurethral resection of the prostate (TURP) has led to the development of alternative energy sources, in an attempt to overcome some of these. Early reports of aquablation (water jet-based prostate resection) for lower urinary tract symptoms due to benign prostatic hyperplasia suggest efficacy similar to that of TURP. We present the two-year results of an ongoing trial. Methods: A prospective single-arm trial at three centres in Australia and New Zealand with 2-year follow-up. Participants were men aged 50–80 years with moderate-to-severe LUTS as determined by urodynamics. All patients underwent aquablation under image guidance. Outcomes for this study include safety (determined by adverse event reporting), IPSS, Qmax, and PVR. Results: Twenty-one men underwent aquablation, with a mean age of 69.7 (range 62–78) years, and prostate volume of 57.2 (30–102) mL. Two-year follow-up was available at 2 sites (N = 17 treated, 14 with visits at 2 years). Mean IPSS score improved from 23.4 at baseline to 7.1 at 12 months and 6.6 at 24 months. Qmax improved from 8.4 cc/sec at baseline to 15.3 sec at 24 months. PVR decreased from 144 cc at baseline to 43 cc at followup. There were no Clavien-Dindo grade 3–4 adverse events. Conclusions: Aquablation is a new method of prostate ablation showing functional improvement which compares favourably to other BPH technologies. This phase II study provides early evidence to support the long-term safety and effectiveness of aquablation for symptomatic BPH.